Satellos Bioscience And 2 Other TSX Penny Stocks To Watch

In This Article:

As 2025 begins, the Canadian market reflects on a stellar year with the TSX gaining 18%, driven by strong economic growth and rising corporate profits. In this climate, investors are increasingly considering diverse opportunities, including penny stocks—an often overlooked yet intriguing segment of the market. While traditionally associated with high risk, these smaller or newer companies can offer unique growth potential when backed by robust financials and solid fundamentals.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

Mandalay Resources (TSX:MND)

CA$4.00

CA$379.39M

★★★★★★

Pulse Seismic (TSX:PSD)

CA$2.35

CA$122.01M

★★★★★★

Silvercorp Metals (TSX:SVM)

CA$4.36

CA$961.62M

★★★★★★

PetroTal (TSX:TAL)

CA$0.63

CA$583.7M

★★★★★★

Findev (TSXV:FDI)

CA$0.50

CA$15.47M

★★★★★★

Foraco International (TSX:FAR)

CA$2.45

CA$241.16M

★★★★★☆

NamSys (TSXV:CTZ)

CA$1.20

CA$30.89M

★★★★★★

East West Petroleum (TSXV:EW)

CA$0.035

CA$3.62M

★★★★★★

Orezone Gold (TSX:ORE)

CA$0.65

CA$307.33M

★★★★★☆

Hemisphere Energy (TSXV:HME)

CA$1.87

CA$178.48M

★★★★★☆

Click here to see the full list of 945 stocks from our TSX Penny Stocks screener.

Let's review some notable picks from our screened stocks.

Satellos Bioscience

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Satellos Bioscience Inc. is a biotechnology company focused on developing regenerative therapeutics for degenerative muscle diseases, primarily operating in Canada and Australia, with a market cap of CA$100.16 million.

Operations: Satellos Bioscience Inc. has not reported any revenue segments.

Market Cap: CA$100.16M

Satellos Bioscience Inc., a pre-revenue biotechnology firm, recently completed a CA$56.96 million follow-on equity offering, bolstering its cash reserves to support ongoing clinical trials. The company is advancing its Phase 1b trial for Duchenne muscular dystrophy (DMD), having successfully dosed the first participant without adverse effects. Despite having no debt and sufficient cash runway for over a year, Satellos faces challenges with volatile share prices and increasing losses. The recent appointment of Stephanie Brown to the board brings significant industry experience, potentially aiding in strategic development as the company navigates its unprofitable status.

TSX:MSCL Financial Position Analysis as at Jan 2025
TSX:MSCL Financial Position Analysis as at Jan 2025

Azimut Exploration

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Azimut Exploration Inc. is involved in the acquisition, exploration, and evaluation of mineral properties in Canada with a market capitalization of CA$53.13 million.